Nuveen LLC Makes New Investment in Voyager Therapeutics, Inc. $VYGR

Key Points

• Nuveen LLC has made a new investment in Voyager Therapeutics, acquiring 108,789 shares valued at approximately $368,000, representing about 0.20% ownership in the company.
• Several institutional investors have increased their stakes in Voyager Therapeutics, with CWM LLC boosting its holdings by 856.3% to own 10,471 shares.
• Voyager Therapeutics recently reported a loss of ($0.57) EPS for the quarter, missing analysts' expectations, alongside a revenue of $5.20 million against a forecast of $9.50 million.

Nuveen LLC acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 108,789 shares of the company's stock, valued at approximately $368,000. Nuveen LLC owned about 0.20% of Voyager Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its position in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Voyager Therapeutics during the 4th quarter worth $29,000. Virtus Investment Advisers Inc. grew its position in Voyager Therapeutics by 59.0% during the 4th quarter. Virtus Investment Advisers Inc. now owns 20,105 shares of the company's stock worth $114,000 after purchasing an additional 7,457 shares during the last quarter. CWM LLC boosted its holdings in shares of Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company's stock valued at $35,000 after acquiring an additional 9,376 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Voyager Therapeutics by 3.0% in the fourth quarter. Northern Trust Corp now owns 418,745 shares of the company's stock valued at $2,374,000 after acquiring an additional 12,374 shares in the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Wedbush lowered their target price on shares of Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the stock. According to data from MarketBeat, Voyager Therapeutics presently has an average rating of "Buy" and an average price target of $13.25.

Voyager Therapeutics Trading Up 9.3%

VYGR stock opened at $4.24 on Friday. The company has a market cap of $235.19 million, a P/E ratio of -2.29 and a beta of 0.90. Voyager Therapeutics, Inc. has a 52 week low of $2.64 and a 52 week high of $8.27. The company's 50-day moving average price is $3.37 and its 200 day moving average price is $3.42.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). The company had revenue of $5.20 million for the quarter, compared to analysts' expectations of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. On average, equities research analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.